With a total market value of $0, Teva Pharma has with a 52 week low of $15.22 and a 52 week high of $52.66.
Mizuho Securities Usa Inc increased Teva Pharmaceutical Inds Ltd (TEVA) stake by 185.23% reported in 2016Q4 SEC filing. For the next year, analysts anticipate that the firm will report sales of $22.10 billion per share, with estimates ranging from $21.39 billion to $22.90 billion. Analyst's mean target price for TEVA is $25.76 while analysts mean recommendation is 3.00. In our view, Teva's global search for a new CEO has been completed with success. The business had revenue of $5.69 billion during the quarter, compared to analysts' expectations of $5.72 billion. Therefore 27% are positive.
Teva Pharmaceutical Industries Limited is a pharmaceutical company. During the same period in the prior year, the firm earned $1.25 EPS. Guggenheim initiated the stock with "Buy" rating in Friday, September 11 report. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has "Buy" rating given on Monday, November 23 by Goldman Sachs. RBC Capital Markets has "Sector Perform" rating and $66 target. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has "Hold" rating given on Friday, November 4 by HSBC. The third largest holder is Fmr Llc, which now holds $662.81 million worth of this stock and that ownership represents almost 4.28% of its market capitalization. SELL rating has been given by 0 analyst (s) and 1 analyst (s) given BUY rating to the stock. With a return potential of almost 75%, the stock's consensus target price stands at $27.06. Its down 11.44% from 36,700 shares previously.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings data on Thursday, August 3rd. The stock rose 11.10% or $1.72 reaching $17.22 per share.
Described by Teva as a "seasoned veteran" of the pharma industry, Schultz is now CEO of Lundbeck and has held a board-level position at Novo Nordisk. Blackrock Advisors Ltd invested in 122,204 shares or 0% of the stock. And today, the specialty pharmaceutical company finally did. Look at its top three institutional owners. This company shares are 64.06% off its target price of $25.43 and the current market capitalization stands at $15.5B. Since the stock's all-time high ($72.31) in 2015, it fell 79% to a multiyear low of $15.22 in the past month.
A number of other analysts have also recently commented on the stock. Investors of record on Tuesday, August 29th will be paid a $0.085 dividend. It has a 15.67 P/E ratio. If you are viewing this piece of content on another site, it was stolen and republished in violation of USA and worldwide copyright legislation. FMR LLC grew its stake in Teva Pharmaceutical Industries Limited by 16.7% during the 2nd quarter. Franklin Resources Inc. grew its stake in Teva Pharmaceutical Industries Limited by 11.1% during the 2nd quarter. Over the course of his career, Mr. Schultz has developed a unique perspective overseeing generic and specialty drug portfolios, while managing complex business operations around the world.
Teva hasn't been the only generic drugmaker struggling of late, as price erosion, decreased volume and increased generic approvals by the Food and Drug Administration have weighed on the industry.